SEC Comment Letter for Immunovant, Inc. (IMVT) (CIK 0001764013) (IMVT) — Apr 8, 2020
Immunovant, Inc. (IMVT) (CIK 0001764013)
Date: April 8, 2020 · CIK: 0001764013 · Accession: 0000000000-20-003020
AI Filing Summary & Sentiment
Letter
April 7, 2020 Peter Salzmann, M.D. Chief Executive Officer Immunovant, Inc. 320 West 37th Street New York, NY 10018 Re:Immunovant, Inc. Draft Registration Statement on Form S-1 Submitted April 1, 2020 CIK No. 0001764013 Dear Dr. Salzmann: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alison A. Haggerty, Esq.
Show Raw Text
April 7, 2020
Peter Salzmann, M.D.
Chief Executive Officer
Immunovant, Inc.
320 West 37th Street
New York, NY 10018
Re:Immunovant, Inc.
Draft Registration Statement on Form S-1
Submitted April 1, 2020
CIK No. 0001764013
Dear Dr. Salzmann:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alison A. Haggerty, Esq.